Head-to-head comparison
| Property | TB-500 | IGF-1 LR3 |
|---|---|---|
| Category | Recovery | Muscle & Growth |
| Legal Status | Reclassification Pending | Research Only |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~4 hours | ~20–30 hours |
| Mol. Weight | 4,963 Da | 9,117 Da |
| Side Effects | Headache, Nausea, Injection site pain | Hypoglycemia (dose-dependent, serious), Fatigue, Jaw pain |
Key differences
- Primary role: TB-500 promotes tissue repair, wound healing, and anti-inflammation; IGF-1 LR3 promotes muscle growth, cell proliferation, and anabolic signaling.
- Mechanism: TB-500 upregulates actin to enhance cell migration and has anti-inflammatory properties; IGF-1 LR3 binds the IGF-1 receptor to activate PI3K/Akt and MAPK pathways for cell growth and proliferation.
- Modification: TB-500 is a synthetic fragment of thymosin beta-4; IGF-1 LR3 is a modified IGF-1 with an extended N-terminal sequence that reduces IGF binding protein affinity, increasing its half-life and potency.
- Half-life: TB-500 has an estimated half-life of a few hours with effects persisting longer; IGF-1 LR3 has a half-life of approximately 20–30 hours (vs 12–15 minutes for native IGF-1).
- Safety concerns: IGF-1 LR3's potent growth-promoting effects raise theoretical concerns about uncontrolled cell proliferation; TB-500 has a milder safety profile focused on tissue repair.
- Dosing: TB-500 is typically dosed at 2–5 mg twice weekly during loading; IGF-1 LR3 is typically dosed at 20–100 mcg daily, often injected locally into target muscles.
- Evidence base: TB-500 has preclinical and extensive veterinary data; IGF-1 LR3 is well-characterized biochemically but has limited published human clinical studies for off-label use.
The verdict
TB-500 and IGF-1 LR3 are not interchangeable — they address different biological needs. TB-500 is for tissue repair and wound healing, making it appropriate when something is damaged. IGF-1 LR3 is an anabolic growth factor for muscle hypertrophy and cell proliferation, appropriate for growth-focused protocols. IGF-1 LR3 carries higher theoretical risk due to its potent growth-promoting effects. For pure recovery, TB-500 is the safer and more targeted option. For anabolic purposes, IGF-1 LR3 is the more direct tool.
Frequently asked questions
They work through different pathways — TB-500 for tissue repair via actin/cell migration and IGF-1 LR3 for anabolic growth via IGF-1 receptor signaling. Some protocols combine both for comprehensive recovery plus growth. No clinical studies have evaluated this combination.
IGF-1 LR3's potent cell proliferation effects raise theoretical concerns about uncontrolled growth in sensitive tissues. It has a well-characterized biochemical profile but limited published human safety data for off-label use. TB-500 has a milder safety profile by comparison. Any use should consider these growth-promoting risks seriously.
For injury repair (torn muscle, connective tissue damage), TB-500's tissue healing properties are more directly relevant. For muscle growth and hypertrophy after recovery, IGF-1 LR3's anabolic signaling is more targeted. They address different phases of the recovery-to-growth continuum.
The LR3 modification adds 13 amino acids to the N-terminus, which reduces binding to IGF binding proteins that normally inactivate IGF-1. This increases IGF-1 LR3's half-life from minutes to approximately 20–30 hours and significantly increases its bioavailability and potency.
Thymosin beta-4 and its fragments are prohibited by WADA (World Anti-Doping Agency) under the S2 category. TB-500 gained notoriety in horse racing where it was widely used. IGF-1 is also banned by WADA under growth factors. Both are prohibited in competitive sport.